AI capabilities are rapidly advancing beyond theory. Today's frontier models can troubleshoot complex laboratory experiments from a simple cell phone picture, often outperforming human PhDs. This dramatically lowers the barrier to entry for conducting sophisticated biological research.

An oncology leader views AI's most powerful near-term application as handling tedious logistical and bureaucratic tasks, not discovering novel molecules. By automating paperwork and trial planning, AI can liberate scientists to spend more time on deep, creative thinking that drives breakthroughs.

Google is moving beyond AI as a mere analysis tool. The concept of an 'AI co-scientist' envisions AI as an active partner that helps sift through information, generate novel hypotheses, and outline ways to test them. This reframes the human-AI collaboration to fundamentally accelerate the scientific method itself.

In its current form, AI primarily benefits experts by amplifying their existing knowledge. An expert can provide better prompts due to a richer vocabulary and more effectively verify the output due to deep domain context. It's a tool that makes knowledgeable people more productive, not a replacement for their expertise.

Contrary to sci-fi visions, the immediate future of AI in science is not the fully autonomous 'dark lab.' Prof. Welling's vision is to empower human domain experts with powerful tools. The scientist remains crucial for defining problems, interpreting results, and making final judgments, with AI as a powerful collaborator.

In high-stakes fields like pharma, AI's ability to generate more ideas (e.g., drug targets) is less valuable than its ability to aid in decision-making. Physical constraints on experimentation mean you can't test everything. The real need is for tools that help humans evaluate, prioritize, and gain conviction on a few key bets.

The tool's real impact is empowering non-specialists, like Shopify's CEO, to experiment with and improve AI models. This dramatically expands the talent pool beyond the few thousand elite PhDs, accelerating progress through broad-based tinkering rather than just isolated AGI breakthroughs.

The ultimate goal isn't just modeling specific systems (like protein folding), but automating the entire scientific method. This involves AI generating hypotheses, choosing experiments, analyzing results, and updating a 'world model' of a domain, creating a continuous loop of discovery.

An ordinary citizen, Paul Cunningham, used off-the-shelf AI like ChatGPT and Google's AlphaFold to design a custom mRNA vaccine that shrank his dog's tumor by 75%. This demonstrates the revolutionary potential of AI to empower individuals to solve complex scientific problems once exclusive to specialized experts.